The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis - Kazuya Tanimura,
Revefenacin for COPD Patients With Suboptimal PIFR | Journal of The COPD Foundation
Long‐acting muscarinic antagonists and small airways in asthma: Which link? - Cazzola - 2021 - Allergy - Wiley Online Library
The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review | European Respiratory Society
Efficacy and cardiovascular safety of LAMA in patients with COPD: a systematic review and meta-analysis | Journal of Investigative Medicine
Long-Acting Muscarinic Receptor Antagonists (LAMA) in Clinical Development | Download Scientific Diagram
Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
inhaled drugs for asthma and COPD | Download Table
Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression - Yuji Oba, Nazir A. Lone, 2015
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial - The Lancet
Long-Acting Muscarinic Antagonists (LAMAs) For Asthma
Breathe Better on Twitter: "If your doctor prescribes a long-acting muscarinic antagonist (LAMA) with an inhaled corticosteroid, make sure they explain how to use the inhaler properly because it's different than those
Just Breathe: Clinical Updates in the Treatment of Asthma and COPD - ppt download
Muscarinic Antagonist - an overview | ScienceDirect Topics
Table 1 from Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma. | Semantic Scholar